NervGen Q2 2026 loss reflects continued spending on NVG-291, NVG-300 development, company saysPUBT·Aug 13 at 07:08 AMNGEN+5.68%
NervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesUnusual Whales·Aug 13 at 06:33 AMNGEN+5.68%
This Halliburton Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesdaybenzinga_article·Jul 14 at 05:50 AMHAL-0.98%IRT-0.24%
NervGen Pharma launches US$ 50 million at-the-market equity offering via Leerink PartnersPUBT·Jul 2 at 04:24 PMNGEN+5.68%
H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)Tip Ranks·Jun 11 at 08:46 AMNGEN+5.68%
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study | NGEN Stock NewsStockTitan·May 25 at 10:15 PMNGEN+5.68%
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga_article·May 22 at 12:05 PMAKTX+0.77%NGEN+5.68%
